Background
==========

Comfrey belongs to the family Boraginaceae. Three plant species in the genus *Symphytum*contribute to the crop known as comfrey, *Symphytum officinale*L. (wild or common comfrey; the major comfrey species), *S. asperum*Lepechin (prickly or rough comfrey), and *S. x uplandicum*Nyman (quaker, Russian, or blue comfrey; a natural hybrid of *S. officinale*L. and *S. asperum*Lepechin). *Symphytum officinale*L. is a tall perennial with large hairy leaves and small purple flowers \[[@B1]\]. Comfrey has been used as an herbal medicine for more than two thousand years for the treatment of broken bones, tendon damage, ulcerations in the gastrointestinal tract, and lung congestion, as well as for wound healing and/or reducing joint inflammation when it is applied externally \[[@B2]\].

In addition to essential nutrients, comfrey also contains pyrrolizidine alkaloids (PAs). PAs are constituents of over 6000 plants, and many of them are hepatotoxic and carcinogenic in humans and animals \[[@B3]\]. In the liver, PAs are transformed to pyrroles by the mixed-function oxidases. Pyrroles exert their toxic effect by reacting with cellular macromolecules, including proteins and DNA \[[@B4]\]. Therefore, comfrey\'s therapeutic use might increase the risk of liver toxicity. Many countries including Canada, Germany, and the UK, have restricted its availability. In 2001, the US Food and Drug Administration requested voluntary compliance for the removal of products containing comfrey \[[@B5]\].

The major hepatotoxic manifestation in humans ingesting comfrey is the hepatic veno-occlusive lesion (VOD) \[[@B6],[@B7]\], also called sinusoidal obstruction syndrome (SOS) \[[@B8]\]. Comfrey is also carcinogenic in rats, which suggests the potential tumorigenic effects of the plant \[[@B9]\]. Hepatocellular adenomas were induced in rats receiving a diet containing comfrey. Feeding rats comfrey leaves produced a dose-dependent reduction in survival and an increase in liver tumor incidence \[[@B9]\]. Comfrey roots are much more toxic than the leaves.

In a previous study, we developed evidence indicating that the liver tumors induced by feeding rats 2% comfrey root were generated by a genotoxic mechanism and that the PAs in the plant were responsible for mutation induction and tumor initiation in rat liver \[[@B10]\]. Considering the fact that rats tolerate diets containing up to 33% comfrey leaves and 8% comfrey roots for relatively long periods of time (at least 6 months) \[[@B9]\], in the present study, we evaluated the mutagenicity of 8% comfrey root. Using a toxicogenomic approach, we analyzed the changes in global gene expressions in the liver of rats following comfrey-treatment.

Results
=======

Growth curve of rats fed with 8% comfrey root
---------------------------------------------

Male Big Blue transgenic rats were fed with 8% comfrey root for 12 weeks. The mean body weight of the comfrey-fed rats was less than that of the vehicle controls throughout the study (Figure [1](#F1){ref-type="fig"}). Rats fed with comfrey weighed 5%, 23%, and 35% less than the control rats after 1, 6, and 12 weeks of the study, respectively, and displayed little weight gain after 6 weeks of feeding with comfrey.

Mutant frequency (MF) in the liver *cII*gene of comfrey-fed rats
----------------------------------------------------------------

The results of *cII*MF analyses in the comfrey-fed and control rats are shown in Figure [2](#F2){ref-type="fig"}. DNA from each liver was packaged 2--4 times either to confirm the MF or to obtain a minimum of 2 × 10^5^plaque-forming units for mutant detection. The MF for rats fed with 8% comfrey was 139 ± 35 (SD) × 10^-6^, which was similar to the MF previously detected in 2% comfrey-fed rats \[[@B10]\] and significantly increased over the control group (30 ± 16 × 10^-6^, *P*\< 0.001).

Mutation spectrum in the liver *cII*gene from comfrey-fed rats
--------------------------------------------------------------

Comfrey-induced mutations in the liver *cII*gene were evaluated by DNA sequence analysis of 106 mutants isolated from 6 rats fed a diet containing 8% comfrey root. Since mutations that were found more than once among the mutants isolated from a single animal were assumed to be siblings and to represent only one independent mutation, a total of 99 independent mutations were identified. Table [1](#T1){ref-type="table"} summarizes the types of *cII*mutations observed in the livers of rats fed 8% comfrey compared with mutation spectra of control and 2% comfrey-fed rats that we reported previously \[[@B10]\]. The overall pattern of mutations in 8% comfrey-fed rats differed significantly from controls (*P*\< 0.0001), but did not differ from 2% comfrey-fed rats. Among the independent mutations, about 85% from both the comfrey-treated and control rats were base pair substitutions. G:C → T:A transversion (41%) was the major type of mutation in the 8% comfrey-fed rats, whereas G:C → A:T transition was the predominant mutation in the controls. In addition, a 13% frequency of tandem base substitutions was observed among the mutations from the 8% comfrey-fed rats. The 8% comfrey-fed rats had more large deletions than control rats, although the percentages of frameshift mutations were the same.

Gene expression regulated by comfrey-treatment
----------------------------------------------

In order to determine gene expression changes associated with comfrey exposure, we employed the Genome Survey Microarray, which contains 26,857 verified rat genes. We isolated total RNA from the livers of 6 control and 6 comfrey-fed rats. For the purpose of visualizing the data, the intensities of the whole rat gene data were analyzed by Principal Components Analysis within ArrayTrack (Figure [3](#F3){ref-type="fig"}). It demonstrates that one array of sample 6 from the control group appears to be quite different from the rest of the arrays, which was further identified as an outlier array by the Pearson\'s correlation coefficient of pair-wise log2 intensity correlation (data not shown). This outlier was excluded from further data analysis. A separation between control and comfrey-treated groups was clearly observed, suggesting that there was a clear comfrey-treatment effect on liver gene expression (Figure [3](#F3){ref-type="fig"}). To select significant genes, minimum requirements were established for both a two-fold change in the gene expression compared to the controls and a *P*-value less than 0.01 for the difference. A total of 2,726 genes satisfied the requirements; 1,235 genes were up-regulated and 1,491 genes were down-regulated in response to comfrey treatment (Figure [4](#F4){ref-type="fig"}). Among the regulated genes, 1,671 were identified by Ingenuity Pathway Analysis. In this study, we focused on genes involved in metabolism, injury of endothelial cells, and liver injury and abnormalities.

Genes associated with drug metabolizing genes
---------------------------------------------

Since the PAs in comfrey require metabolic activation to exert their biological effects, we investigated the gene expression changes of drug metabolizing genes. We observed the up- or down-regulation of many cytochrome P450 genes (e.g., Cyp2c12, Cyp3a18, Cyp4a12, Cyp26), glutathione *S*-transferases (Gsta3, Gstm3, and Gstp1), ATP-binding cassette transporters (e.g., Abcb9 and Abcc3), and other metabolism-associated genes, including NAD(P)H oxidoreductase (Nqo1) and aldehyde dehydrogenase (Aldh1a1). Table [2](#T2){ref-type="table"} shows the significant changes in gene expression related to phase I, II, and III drug metabolizing genes.

Genes involved in injury of endothelial cells
---------------------------------------------

Considering the involvement of sinusoidal endothelial cells and sometimes hepatic venular endothelial cells in VOD/SOS \[[@B8]\], we focused on genes expressed in endothelial cells. Table [3](#T3){ref-type="table"} summarizes the alteration of genes related to cell death, apoptosis, and cell growth of endothelial cells. For example, we observed the up-regulation of previously reported tumor necrosis factors (Tnfsf10, Tnfrsf6, and Tnfrsf12a), transforming growth factor (Tgfb1 and Tgfb2), and other genes (such as, Mmp2, PAI-1 or Serpine1, Plaur, Col4a2, and Edn1) \[[@B8],[@B11],[@B12]\]. Several novel genes were responsive to comfrey treatment, including activating transcription factor 3 (Atf3), B-cell cLL/lymphoma 2 (Bcl2), caspase 1 (Casp1), mitogen-activated protein kinase 9 (Mapk9), and secreted phosphoprotein 1 (Spp1).

Genes involved in liver injury and abnormalities
------------------------------------------------

Endothelial damage can lead to hepatocellular injury, and fibrotic reaction in the sinusoids is characterized as the later stages of VOD/SOS. Chronic comfrey treatment also resulted in the induction of a number of genes involved in liver injury and abnormalities. Significantly changed genes were divided into subsets based on functionality, and categories included cell death, growth, fibrosis, morphology, and liver cancer development (Table [4](#T4){ref-type="table"}). Sixteen genes were functionally categorized in liver cell death. Besides the tumor necrosis factors and transforming growth factor, comfrey treatment resulted in strong up-regulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a) and heme oxyenase 1 (Hmox1), as well as down-regulation of epidermal growth factor (Egf) and CCAAT/enhancer binding protein beta (Cebpb). Of note, genes involved in cell growth were up-regulated along with the genes involved in liver cell death, such as cyclin E1 (Ccne1), hepatocyte growth factor (Hgf), and tissue inhibitor of metalloproteinase 1 (Timp1).

Liver fibrosis is the hallmark of all chronic liver diseases, irrespective of their origin. Ingenuity Pathway Analysis showed that sixteen significantly regulated genes appeared to have a role in liver fibrosis (Table [4](#T4){ref-type="table"}). Most of them encode cytokines (Hgf, Igf1, Lif, Tgfb1, and Tnfrsf6), angiogenic molecules (Agt, and Agtr1a), chemokines and their receptors (Ccr2, Cxcl4, and Cxcl12), coagulation cascade genes (PAI-1/Serpine1 and F11), and cytoskeletal molecules (Krt2-8). Moreover, eight genes related to the development of liver cancer were among the most discriminating genes involved in cancer development, such as growth arrest and DNA damage inducible 45 alpha (Gadd45a), B-cell cLL/lymphoma 2 (Bcl2), N-myc downstream regulated 1 (Ndr1), and xeroderma pigmentosum complementation group C (Xpc).

Discussion
==========

Comfrey was one of the most popular herbal teas in the world, including the United States. Although its popularity has declined due to the understanding of its dangers, it is still available commercially in several forms. The regular use of comfrey is a potential health risk owing to the presence of PAs. Comfrey contains as many as nine PAs, including acetyl intermedine, acetyl lycopsamine, echimidine, intermedine, lasiocarpine, lycopsamine, symlandine, symphytine, and symviridine \[[@B13]-[@B15]\]. The PA content of comfrey is less than 1% and depends on the plant part \[[@B15]\]. Higher PA concentrations occur in the roots of comfrey than in the leaves, and commercially available comfrey tablets containing high levels of PAs are likely to be derived from comfrey roots \[[@B16],[@B17]\]. PAs are the leading plant toxins associated with disease in humans and animals.

Several cases of VOD/SOS associated with comfrey ingestion have been reported in humans \[[@B6],[@B7],[@B18]-[@B20]\], as well as in experimental animals \[[@B21]\]. Deleve and her colleagues \[[@B22]\] have developed a reproducible animal model of hepatic VOD, in which the rats are gavaged with a single dose of PA, monocrotaline. The model exhibits the characteristic clinical and histological features of hepatic VOD, including the earliest manifestations (progressive injury to the sinusoidal endothelial cells and central vein endothelium), early VOD (centrilobular coagulative necrosis and severe sinusoidal injury, hemorrhage, and central vein endothelial damage), and late VOD (fibrotic occulusion of the central veins) \[[@B22]\]. Comfrey and the specific alkaloids in comfrey (e.g., symphytine and lasiocarpine) induce hepatoadenoma and hemangioendothelial sarcomas in rats \[[@B9],[@B23],[@B24]\]. The mechanisms by which toxicity and carcinogenicity are produced are still not fully understood. Gene expression profiling offers a powerful approach for identifying differentially expressed genes and identifying mechanisms.

Gene expression was markedly affected (Figure [3](#F3){ref-type="fig"}) in the livers of rats exposed to 8% comfrey root, a dose that resulted in significant decreases in body weight (Figure [1](#F1){ref-type="fig"}) and increases in liver MF (Figure [2](#F2){ref-type="fig"}). Out of 26,857 genes evaluated, the expression of 4,132 (15%) and 9,937 (37%) genes were altered more than 2-fold and 1.5-fold, respectively. At *P*-values of 0.01 and 0.05, 7,518 (28% of expressed genes) and 1,0341 (39%) genes, respectively, displayed a significant effect after comfrey-treatment compared to control group. In this study, differential gene expression was considered significant for genes showing at least a 2-fold up- or down-change, and a *P*\< 0.01. In total, 2,726 genes (10%) satisfied the requirements and about half of them were down-regulated and half up-regulated in response to comfrey exposure (Figure [4](#F4){ref-type="fig"}). Such a large number of significantly altered genes may partly reflect the therapeutic effects of comfrey exerted through plant components other than PAs \[[@B15]\]. In the present study, we concentrated on the analysis of genes involved in metabolism, injury of endothelial cells, and liver injury and abnormalities.

Liver is the major organ for biotransformation of xenobiotics and drugs. PAs are metabolically activated to toxic, alkylating pyrroles by mixed-function oxidases. The cytochrome P450 (Cyp) superfamily contains 57 genes and plays a critical role in the phase I metabolism of a variety of xenobiotics including drugs, carcinogens, steroids and eicosanoids \[[@B25]\]. In the present study, comfrey exposure resulted in changes in the expression of 19 Cyp genes (Table [2](#T2){ref-type="table"}). Among phase I, II, and III drug metabolizing genes, Cyp2c12, Cyp7a1, Cyp26, Gsta3, and Abcc3 were increased 6-21-fold. In contrast, Cyp2c, Cyp39a1, Gstm3, Abcc8, and others were reduced in the comfrey-treated livers. It is known that many herbal/dietary constituents form reactive intermediates capable of irreversibly inhibiting various Cyps (reviewed in \[[@B25]\]). The resultant metabolites lead to Cyp inactivation by chemical modification of the heme, the apoprotein, or both, as a result of covalent binding of modified heme to the apoprotein. Phase II consists of conjugating enzymes, such as glutathione *S*-transferases (GSTs), UDP-glucuronosyltransferases (UGTs), and sulfatases. GSTs also participate in oxidative stress release pathways. The altered expression of phase I and phase II enzymes along with altered drug transport proteins (phase III) could contribute to the increased susceptibility of rats to carcinogenic chemicals, such as comfrey.

Sinusoidal endothelial cells are more susceptible than hepatocytes to PAs that cause VOD/SOS \[[@B22]\]. Functional annotation extracted from Ingenuity Pathway Analysis revealed that many of the transcriptional responses were associated with the apoptosis, cell death, adhesion, and cell movement of endothelial cells (Table [3](#T3){ref-type="table"}). The genes in these pathways were highly expressed in comfrey-treated livers; these genes included the endothelial cell markers plasminogen activator inhibitor type 1 (PAI-1, also known as Serpine1 and Serpine2) and tissue plasminogen activator (Plat), and the cytokine tumor necrosis factors (Tnfrsf6, Tnfrsf12a, and Tnfsf10), and transforming growth factors (Tgfb1 and Tgfb2). Induction of a number of genes involved in the injury of endothelial cells was also detected, including endothelin 1 (Edn1), urokinase plasminogen activator receptor (Plaur), collagen type IV alpha 2 (Col4a2), matrix metalloproteinase 2 (Mmp2), mitogen-activated protein kinase 9 (Mapk9), and secreted phosphoprotein 1 (Spp1). It has been reported that Edn1 is a mediator of hepatic sinusoidal constriction, and increased activity of matrix metalloproteinases is responsible for changes of sinusoidal endothelial cells \[[@B11]\]. Elevated plasma PAI-1 levels are useful in distinguishing VOD/SOS \[[@B26]\]. Endothelial injury is the initiating event in the cascade of events leading to the hepatic changes and clinical manifestation of VOD/SOS \[[@B27]\]. Our results offer a more comprehensive overview of the molecular responses to comfrey exposure by expression of multiple genes in liver endothelial cells.

PAs in comfrey can reach the hepatocytes via the sinusoidal blood, and their toxic metabolites lead to immediate damage to the hepatocytes \[[@B4]\]. Genes involved in liver cell death and growth were also induced or repressed in response to comfrey treatment (Table [4](#T4){ref-type="table"}), including tumor necrosis factors, transforming growth factor β, chemokine receptor CCR2 gene (Ccr2), heme oxygenase 1 (Hmox1), immediate early response 3 (Ier3), cyclin-dependent kinase inhibitor (Cdkn1a), inhibin beta A (Inhba), and tissue inhibitor of metalloproteinase 1 (Timp1). It is well known that Hmox1 induction is a protective mechanism against the oxidative stress associated with liver injury \[[@B28]\], and that elevated Hgf could protect hepatocytes from injury or promote hepatocellular regeneration \[[@B29]\]. Since Inhba, so-called activin A, is a negative regulator of hepatocyte cell growth \[[@B30]\], the decreased expression of Inhba observed after comfrey treatment suggests the induction of hepatic growth.

Necrosis of hepatocytes and mesenchymal cells follows comfrey-induced liver cell injury, and functional cells are replaced by fibrotic tissues \[[@B27],[@B31],[@B32]\]. In the present study, we observed 16 genes involved in the function of liver fibrosis by Ingenuity Pathway Analysis (Table [4](#T4){ref-type="table"}). Liver fibrosis is characterized by cell proliferation and the accumulation of extracellular matrix components and is mediated by cytokines and growth factors, of which TGF-β1 appears to be a key mediator \[[@B32]\]. The up-regulation of cytokines Hgf and Tnfrsf6 and down-regulation of Igf1 and Lif play an important role in the pathogenesis of liver injury and fibrosis. Decreased serum Igf-1 levels provide a useful index of hepatocellular dysfunction and impaired nutritional status, and increased Hgf appears to limit liver fibrosis \[[@B33]\]. Agt and Agtr1a, cytokines with vasoactive properties, also regulate liver fibrogenesis. Chemokines have a much wider biological role including angiogenesis, carcinogenesis, and cell cycle control \[[@B34]\]. Chemokines in the liver (Cxcl4 and Cxcl12) may modulate the progression of liver fibrosis through their actions on hepatic stellate cells.

PA-induced DNA damage in the liver (endothelial cells and hepatocytes), if not repaired prior to DNA synthesis, might produce replication errors and mutations, which eventually could result in the development of neoplasmas in the treated animals. We determined MFs in the liver *cII*gene of Big Blue transgenic rats. After feeding with 8% comfrey root for 12 weeks, we observed a 4-fold higher MF in the liver *cII*gene compared to the controls (Figure [2](#F2){ref-type="fig"}). The induction of mutation was similar to that reported previously for rats fed with 2% comfrey root \[[@B10]\]. These observations suggest that the rats could not tolerate the feeding of roots in concentrations over 2%, in terms of mutation induction. Furthermore, the overall pattern of mutations induced by 8% comfrey in liver was similar to that in the livers of rats fed 2% comfrey root (Table [1](#T1){ref-type="table"}), whereas both the 2% and 8% comfrey-induced mutation spectra were significantly different from liver controls. In contrast to the G:C → A:T transition that was the predominant mutation in the controls, the major type of mutation in the 8% comfrey-fed rats was G:C → T:A transversion (41%), a mutation that was also induced by riddelliine, a representative genotoxic PA that is tumorigenic for rat liver \[[@B35]\]. In addition, 13% of mutations from the 8% comfrey-fed rats were tandem base substitution, which has been suggested as a mutational signature for the genetic damage of PAs \[[@B36]\]. G:C → T:A transversion may cause the initiation of tumors in the liver of rats fed with comfrey, because it has been reported that more than half of riddelliine-induced liver hemangiosarcomas have a G → T mutation at K-*ras*codon 12 \[[@B37]\]. *p53*mutation also has been detected at an early stage of riddelliine exposure \[[@B38]\]. Mutations are thought to be involved in carcinogenesis because the transition from a normal somatic cell to a cancer cell is due to mutations in protooncogenes, tumor suppressor genes and/or genes that function in the maintenance of genomic stability \[[@B39],[@B40]\]. Comfrey-induced neoplasms in the rat were mostly found in the liver. Hepatocellular adenomas were induced in all experimental groups that received diets containing 1--8% comfrey root or 8--33% comfrey leaves. In addition, a few rats bearing hepatocellular adenomas simultaneously had hemangioendothelial sarcoma of the liver \[[@B9]\]. The first hepatocellular carcinoma (HCC) appearance was 7 months after initiating the 8% comfrey diet.

Ingenuity Pathway Analysis found 8 genes (2 down- and 6 up -regulated) involved in liver cancer development that were altered due to comfrey treatment (Table 5). In mammals, the nucleotide excision repair process is the most important repair pathway for elimination of DNA damage caused by exogenous agents, including UV light, DNA-reactive carcinogens, and some endogenously generated oxidative lesions \[[@B41]\]. Xeroderma pigmentosum group C (Xpc) is implicated in the early steps of this repair pathway. A significantly higher incidence of chemically induced liver and lung tumors is observed in Xpc null mice \[[@B42]\]. Gap junction membrane channel protein beta 1 (Gjb1), also called connexin 32 (Cx32), is the main gap junction protein in hepatocytes and plays an important role in the regulation of signal transfer and growth control in the liver. It has been reported that Cx32 expression decreases gradually as liver disease progresses to cirrhosis and HCC \[[@B43]\], and a low expression of Cx32 mRNAs in HCC tissues is also predictive of the postoperative recurrence of HCCs \[[@B44]\]. Bcl-2 is characterized as an antiapoptotic/oncogenic protein and also functions as an antioxidant. Increased Bcl-2 expression in cirrhotic patients correlates with the development of HCC \[[@B45]\]. Bcl-2 is also expressed in HCC tissues and the increasing Bcl-2 expression associated with HCC progression suggests that the Bcl-2 protein takes part in the formation of HCC \[[@B46]\]. Hgf, identified originally as the most potent mitogen for hepatocytes, is now known to be a cytokine with numerous functions in a wide variety of cells \[[@B47]\]. It is up-regulated in inflammatory liver diseases and stimulates DNA synthesis preferentially in initiated hepatocytes, presumably resulting in tumour promotion \[[@B48]\]. N-myc downstream-regulated gene 1 (Ndr1, or Ndrg1) plays a role in growth arrest and cell differentiation, is induced by several stress conditions, and is overexpressed in many cancers \[[@B49]\]. Expression of Ndrg1 was significantly up-regulated in HCC tissues compared to that of noncancerous and normal liver tissues \[[@B50]\]. Cyclin E (Ccne1), a regulatory subunit of cyclin-dependent kinase 2, is an important regulator for entry into the *S*phase of the mammalian cell cycle. Overexpression of Ccne1 has been observed in many tumors including primary HCCs \[[@B51]\]; overexpression results in chromosome instability and thus may contribute to tumorigenesis \[[@B52]\]. Growth arrest and DNA damage 45 alpha (Gadd45a) is a nuclear protein involved in the maintenance of genomic stability, DNA repair, and the suppression of cell growth \[[@B53]\]. Gadd45a protein levels are higher in liver cirrhotic and neoplastic tissues \[[@B54]\]. Tissue inhibitor of metalloproteinase 1 (Timp1) is a contributory factor to fibrosis of a variety of organs including the liver. Timp1 and other extracellular matrix remodeling genes are implicated in the transition from mild to moderate fibrosis in patients with chronic hepatitis C \[[@B55]\].

Conclusion
==========

The integration of gene expression changes with a mechanistic pathway analysis suggests a scheme for comfrey treatment leading to tumorigenesis via mutation induction (Figure [5](#F5){ref-type="fig"}). The available evidence suggests that active metabolites of PAs in comfrey interact with endothelial and hepatocyte DNA, causing damage to hepatic endothelial cells and hepatocytes. This may result in liver fibrosis and increases in mutation induction, which may be associated with the development of HCC and hemagiosarcoma. We have identified 2,726 genes in the livers of comfrey-fed rats that were differentially expressed. Some of the gene changes are associated with the metabolism, injury of endothelial cells, and liver injury and abnormalities that are postulated to occur as a result of comfrey exposure. This approach provides further insight into the mechanisms involved in the development of VOD/SOS and tumorigenesis after exposure to comfrey.

Materials and methods
=====================

Plant material and animals
--------------------------

Comfrey roots (*Symphytum officinale*) were purchased from Camas Prairie Products (Trout Lake, WA). Male Big Blue Fisher 344 transgenic rats were obtained from Taconic Laboratories (Germantown, NY) through purchase from Stratagene (La Jolla, CA). All animal procedures followed the recommendations of the NCTR Institutional Animal Care and Use Committee for the handling, maintenance, treatment, and sacrifice of the rats.

Comfrey diet and treatments
---------------------------

The comfrey roots were ground into powder using a Wiley Mill, and the comfrey root powder was stored at room temperature until use. NIH-31 pellets (Purina Mills International, Brentwood, MO) were autoclaved and ground into meal form. The base diet was blended with comfrey root powder in a Hobart Mixer to make 8% comfrey root dosed diet, which was provided in rat feeders. The treatment schedule was based on the protocol used in a carcinogenesis assay \[[@B9]\]. Male, 6-week-old Big Blue rats were fed without (vehicle control group) or with 8% comfrey roots for 12 weeks. Six rats from each treatment group were sacrificed at the end of the treatment. The livers were isolated, frozen quickly in liquid nitrogen, and stored at -80°C.

*cII*mutation assay
-------------------

High-molecular-weight genomic DNA was extracted from rat livers using the RecoverEase DNA Isolation Kit (Stratagene) and stored at 4°C until DNA packaging was performed. The packaging of the phage, plating the packaged DNA samples, and determination of MF were carried out following the manufacturer\'s instructions for the λ Select-*cII*Mutation Detection System for Big Blue Rodents (Stratagene). The shuttle vector containing the *cII*target gene was rescued from total genomic DNA with phage packaging extract (Transpack, Stratagene). The plating was performed with the *Escherichia coli*host strain G1250. To determine the total titer of packaged phages, G1250 bacteria were mixed with 1:3000 dilutions of phage, plated on TB1 plates, and incubated overnight at 37°C (nonselective conditions). For mutant selection, the packaged phages were mixed with G1250, plated on TB1 plates, and incubated at 24°C for about 42 h (conditions for *cII*-selection). Under these conditions, phages with wild-type *cII*genes undergo lysogenization and become part of the developing bacterial lawn, whereas phages with mutated *cII*genes undergo lytic growth and give rise to plaques. When incubated at 37°C, phages with wild-type *cII*genes also undergo a lytic cycle, resulting in plaque formation. Assays were repeated until a minimum of 2 × 10^5^plaque-forming units from each sample were examined for mutation. The *cII*MF is defined as the total number of mutant plaques (determined at 24°C) divided by the total number of plaques screened (determined at 37°C).

Sequence analysis of the *cII*mutants
-------------------------------------

The mutants were sequenced according to the method of Mei et al. \[[@B36]\]. The *cII*mutant plaques were selected at random from different animals and replated at low density to verify the mutant phenotype. Single, well-isolated plaques were selected from these plates and transferred to a microcentrifuge tube containing 100 μl of sterile distilled water. The tube was heated at 100°C for 5 min and centrifuged at 12,000 *g*for 3 min. The *cII*target DNA for sequencing was amplified by PCR using primers 5\'-AAAAAGGGCATCAAATTAACC-3\' (upstream) and 5\'-CCGAAGTTGAGTATTTTTGCTG-3\' (downstream). For PCR amplification, 10 μl of the supernatant were added to 10 μl of a PCR Master Mix (Promega, Madison, WI) and the primers. The final concentrations of the reagents were: 1× Taq polymerase reaction buffer, 0.2 μM of each primer, 200 μM of each dNTP, 1.5 mM MgCl~2~, and 0.25 U of Taq DNA polymerase. The PCR reactionwas performed using a PCR System 9700 (Applied Biosystems, Foster City, CA), with the following cycling parameters: a 3 min denaturation at 95°C, followed by 35 cycles of 30 s at 95°C, 1 min at 60°C, and 1 min at 72°C, with a final extension of 10 min at 72°C. The PCR products were isolated using a PCR purification kit (Qiagen, Chatsworth, CA). The *cII*mutant DNA was sequenced with a CEQ Dye Terminator Cycle Sequencing Kit and a CEQ 8000 Genetic Analysis System (Beckman Coulter, Fullerton, CA). The primer for *cII*mutation sequencing was the upstream primer used for the PCR.

Statistical analyses for mutagenicity data
------------------------------------------

Analyses were performed using the SigmaStat 2.03 program (SPSS, Chicago, IL). All of the MF data were expressed as the mean ± standard deviation (SD) from 6 rats per group. Statistical significance was determined by one-way analysis of variance (ANOVA) followed by the Holm-Sidak test. Mutational spectra were compared using the computer program written by Cariello and colleagues \[[@B56]\] for the Monte Carlo analysis developed by Adams and Skopek \[[@B57]\].

RNA isolation and quality control
---------------------------------

Total RNA was isolated from liver tissues of 6 control and 6 comfrey-fed rats using an RNeasy system (Qiagen). The yield of the extracted RNA was determined spectrophotometrically by measuring the optical density at 260 nm. The purity and quality of extracted RNA were evaluated using the RNA 6000 LabChip and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA samples with RNA integrity numbers (RINs) greater than 7.5 were used for microarray experiments performed using Applied Biosystems\' Rat Genome Survey Microarray platform, which is a one channel microarray with chemiluminescence detection, and contains 26,857 probes (60-mer) for the interrogation of 27,088 genes and 1592 controls that track system performance through each experiment.

Preparation of digoxigenin labeled in vitro transcribed cRNA
------------------------------------------------------------

All RNA targets were labeled using the Applied Biosystems RT-IVT Labeling Kit Version 2.0. Briefly, 1.5 μg of total RNA was reverse transcribed via 2 h incubation at 42°C with ArrayScript RT enzyme (Ambion, Austin, TX) and oligo dT-T7 primer. Double stranded cDNA was produced following 2 h incubation with *E. coli*DNA polymerase and RNase H at 16°C. Double-stranded cDNA was purified according to the RT-IVT kit protocol. In vitro transcription was performed by incubation of the cDNA product with T7 RNA polymerase, 0.75 mM Digoxigenin-11-UTP (Roche Applied Science, Indianapolis, IN) and all other NTPs for 9 h. Labeled cRNA was purified according to the RT-IVT kit protocol and analyzed for quality and quantity using standard UV spectrometry and the Bioanalyzer.

Hybridization of labeled cRNA to microarrays and microarray imaging
-------------------------------------------------------------------

Digoxigenin labeled cRNA targets were hybridized to Applied Biosystems Rat Whole Genome Survey Microarrays using the Applied Biosystems Chemiluminescent Detection Kit. Briefly, 15 μg of labeled cRNA targets were fragmented via incubation with fragmentation buffer provided in the kit for 30 min at 60°C. Fragmented targets were hybridized to microarrays during a 16 h incubation at 55°C with buffers and reagents from the Chemiluminescent Detection Kit. Post-hybridization washes and anti-Digoxigenin-Alkaline Phosphatase binding were performed according to the protocol of the kit. Chemiluminescence detection, image acquisition and analysis were performed using Applied Biosystems Chemiluminescence Detection Kit and Applied Biosystems 1700 Chemiluminescent Microarray Analyzer following the manufacturer\'s protocols. Images were auto-gridded and the chemiluminescent signals were quantified, corrected for background, and finally, spot- and spatially-normalized using the Applied Biosystems 1700 Chemiluminescent Microarray Analyzer software version 1.1.

Microarray data analysis
------------------------

Gene expression data from the Applied Biosystems\' Rat Genome Survey Microarray were input to ArrayTrack, a software system developed by the FDA\'s National Center for Toxicological Research for the management, analysis, visualization and interpretation of microarray data \[[@B58]\]. Raw microarray intensity data were normalized per chip to the same median intensity value of 500. Chemiluminescent signals from 1529 control probes that track system performance through each experiment were not used in normalization. The identification of differentially expressed genes based on *t*-tests and fold-change cutoffs, and Principal Component Analysis were conducted within ArrayTrack. Ingenutity Pathway Analysis (Mountain View, CA) was used for pathway and function analysis.
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![**Mean body weight of Big Blue rats fed with 8% comfrey root for 12 weeks**. The data represent the means ± SD of 6 rats from the control (■) and the 8% comfrey root (●) groups.](1471-2105-7-S2-S16-1){#F1}

![**Liver *cII*mutant frequencies in control and 8% comfrey-fed rats**. The data represent the means ± SD from groups of 6 rats. \*Significantly differed from control group (*P*\< 0.001).](1471-2105-7-S2-S16-2){#F2}

![**Principal component analysis for gene expression profiles from livers of control and 8% comfrey-fed rats**. No specific cut off was applied and the intensity of whole rat genome data was used. The red and blue dots indicate control and comfrey-treated samples, respectively.](1471-2105-7-S2-S16-3){#F3}

![**Volcano plots (log2 fold change vs. -log2 *P*-value)**. A gene was identified as significantly changed if the fold change was greater than 2 (up or down) and the *P*-value was less than 0.01 in comparison to the control group. Each group consisted of 5--6 replicates.](1471-2105-7-S2-S16-4){#F4}

![Integration of gene expression with the proposed mechanistic pathway initiated by comfrey treatment leading to tumorigenesis. Responses in boxes represent gene expression observations and arrows in the boxes indicate direction of indicated response.](1471-2105-7-S2-S16-5){#F5}

###### 

Summary of independent mutations in the liver *cII*gene from comfrey-fed and control Big Blue rats

  **Type of mutation**       **Control**\*   **8% comfrey**•   **2% comfrey**•, \*               
  -------------------------- --------------- ----------------- --------------------- ----- ----- -----
  G:C → C:G                  5               11                6                     6     11    6
  G:C → A:T                  20              43                11                    11    24    12
  G:C → T:A                  9               20                40                    41    83    42
  A:T → T:A                  1               2                 4                     4     5     2
  A:T → G:C                  1               2                 6                     6     9     4
  A:T → C:G                  3               7                 4                     4     7     3
  Frameshift                 7               15                14                    14    26    13
  Complex                    0               0                 1                     1     2     1
  Tandem-base substitution   0               0                 13                    13    33    17
  Total mutants screened     46              100               99                    100   200   100

•Spectra for 2% and 8% comfrey-fed rats were significantly different from the controls (*P*\< 0.001). There was no significant difference between the spectra for 2% and 8% comfrey.

\*Data are from literature \[10\].

###### 

Genes involved in drug metabolism altered by comfrey treatment in liver

  **Gene symbol**                 **Gene description**                           **Locus link ID**   **Fold change**   ***P*-value**
  ------------------------------- ---------------------------------------------- ------------------- ----------------- ---------------
  *[Phase I metabolism]{.ul}*                                                                                          
  Cyp2c                           cytochrome P450, family 2, subfamily c         29277               0.03              0.00000
  Cyp2c12                         cytochrome P450, family 2, subfamily c         25011               6.52              0.00000
  Cyp2c39                         cytochrome P450, family 2, subfamily c         29298               0.35              0.00001
  Cyp2d1                          cytochrome P450, family 2, subfamily d         266684              0.38              0.00000
  Cyp2d2                          cytochrome P450, family 2, subfamily d         25053               0.43              0.00002
  Cyp2d3                          cytochrome P450, family 2, subfamily d         24303               0.39              0.00000
  Cyp2d5                          cytochrome P450, family 2, subfamily d         286963              0.44              0.00000
  Cyp3a18                         cytochrome P450, family 3, subfamily a         252931              0.38              0.00060
  Cyp4a3                          cytochrome P450, family 4, subfamily a         298423              0.46              0.00010
  Cyp4a12                         cytochrome P450, family 4, subfamily a         266674              0.36              0.00015
  Cyp4b1                          cytochrome P450, family 4, subfamily b         24307               0.32              0.00008
  Cyp4f5                          cytochrome P450, family 4, subfamily f         286905              4.71              0.00000
  Cyp4f14                         cytochrome P450, family 4, subfamily f         56266               0.48              0.00005
  Cyp4f18                         cytochrome P450, family 4, subfamily f         72054               0.47              0.00014
  Cyp7a1                          cytochrome P450, family 7, subfamily a         25428               6.16              0.00067
  Cyp7b1                          cytochrome P450, family 7, subfamily b         13123               2.15              0.00169
  Cyp11b3                         cytochrome P450, family 11, subfamily b        353498              0.43              0.00032
  Cyp26                           cytochrome P450, family 26                     154985              18.54             0.00005
  Cyp39a1                         cytochrome P450, family 39, subfamily a        56050               0.29              0.00315
  *[Phase II metabolism]{.ul}*                                                                                         
  Gsta3                           glutathione S-transferase, alpha 3             14859               14.47             0.00001
  Gstm3                           glutathione S-transferase, mu 3                81869               0.39              0.00173
  Gstp1                           glutathione S-transferase, pi 1                14869               3.16              0.00001
  *[Phase III metabolism]{.ul}*                                                                                        
  Abcb9                           ATP-binging cassette, subfamily b (MDR/TAP)    63886               0.23              0.00292
  Abcc1                           ATP-binging cassette, subfamily c (CFTR/MRP)   24565               2.65              0.00132
  Abcc3                           ATP-binging cassette, subfamily c (CFTR/MRP)   140668              21.20             0.00006
  Abcc6                           ATP-binging cassette, subfamily c (CFTR/MRP)   81642               0.42              0.00000
  Abcc8                           ATP-binging cassette, subfamily c (CFTR/MRP)   25559               0.10              0.00000

###### 

Genes involved in endothelial cells altered by comfrey treatment in liver

  **Gene symbol**                     **Gene description**                                                                                    **Locus link ID**   **Fold change**   ***P*-value**
  ----------------------------------- ------------------------------------------------------------------------------------------------------- ------------------- ----------------- ---------------
  *[Cell death and apoptosis]{.ul}*                                                                                                                                                 
  \*, • Angpt2                        angiopoietin 2                                                                                          11601               3.45              0.00121
  App                                 amyloid beta (A4) precursor protein                                                                     54226               4.69              0.00000
  Atf3                                activating transcription factor 3                                                                       25389               6.22              0.00010
  Bcl2                                B-cell cLL/lymphoma 2                                                                                   24224               2.41              0.00500
  Bcl2a1                              Bcl2-related protein A1                                                                                 170929              3.43              0.00022
  Bcl2l                               Bcl2-like                                                                                               12048               2.53              0.00000
  Casp1                               caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase)                        25166               2.26              0.00551
  Cnp                                 2\',3\'-cyclic nucleotide 3\' phosphodiesterase                                                         1267                2.37              0.00010
  • Col4a2                            collagen, type IV, alpha 2                                                                              1284                2.81              0.00000
  • Cxcr4                             chemokine receptor (LCR1)                                                                               60628               3.22              0.00186
  Dusp6                               dual specificity phosphatase 6                                                                          116663              2.31              0.00036
  Edn1                                endothelin 1                                                                                            24323               4.87              0.00033
  Fgf1                                fibroblast growth factor 1                                                                              25317               2.05              0.00057
  \*Gpr9                              G protein-coupled receptor 9 (Cxcr3)                                                                    84475               2.02              0.00944
  • Hgf                               hepatocyte growth factor                                                                                24446               3.18              0.00065
  Hmox1                               heme oxygenase 1                                                                                        24451               3.23              0.00064
  Il2                                 interleukin 2                                                                                           116562              0.29              0.00010
  Ins1                                insulin 1                                                                                               24505               0.22              0.00000
  Lrp5                                low density lipoprotein receptor-related protein 5                                                      16973               0.35              0.00010
  Mapk9                               mitogen-activated protein kinase 9                                                                      50658               0.49              0.00009
  Pparg                               peroxisome proliferator activated receptor, gamma                                                       25664               0.32              0.00033
  Serpinf1                            serine (or cysteine) proteinase inhibitor, clade F), member 1                                           287526              0.49              0.00009
  \*Spp1                              secreted phosphoprotein 1                                                                               25353               11.63             0.00003
  \*, • Tgfb1                         transforming growth factor, beta 1                                                                      59086               2.11              0.00002
  Tnfrsf6                             tumor necrosis factor receptor superfamily, member 6                                                    246097              3.40              0.00007
  Tnfsf10                             tumor necrosis factor (ligand) superfamily, member 10                                                   246775              2.19              0.00366
  *[Adhesion]{.ul}*                                                                                                                                                                 
  Anxa1                               annexin 1                                                                                               25380               2.50              0.00009
  Anxa5                               annexin 5                                                                                               25673               4.29              0.00000
  Cd44                                CD44 antigen                                                                                            25406               2.65              0.00004
  Cx3cl1                              chemokine (C-X3-C motif) ligand 1                                                                       89808               2.55              0.00333
  • Cxcl4                             chemokine (C-X-C motif) ligand 4                                                                        56744               3.12              0.00008
  Cyr61                               cysteine rich protein 61                                                                                83476               4.54              0.00000
  •Itga4                              integrin alpha 4                                                                                        16401               5.28              0.00002
  •Itgav                              integrin alpha V                                                                                        16410               2.00              0.00113
  Selplg                              selectin P ligand                                                                                       6404                2.26              0.00088
  *[Cell movement]{.ul}*                                                                                                                                                            
  Agt                                 angiotensinogen                                                                                         24179               0.36              0.00000
  Ccl2                                chemokine (C-C motif) ligand 2                                                                          24770               4.27              0.00026
  Cd151                               CD151 antigen                                                                                           64315               2.13              0.00000
  Cd9                                 CD9 antigen                                                                                             12527               2.10              0.00127
  Ceacam1                             carcinoembryonic antigen-related cell adhesion molecule 1                                               81613               0.49              0.00138
  Cxcl12                              chemokine (C-X-C motif) ligand 12                                                                       24772               0.19              0.00000
  Edil3                               EGF-like repeats and discoidin I-like domains 3                                                         10085               3.57              0.00015
  Efnb2                               ephrin B2                                                                                               13642               0.49              0.00006
  Fgfr1                               Fibroblast growth factor receptor 1                                                                     79114               2.25              0.00002
  Id1                                 Inhibitor of DNA binding 1, helix-loop-helix protein (splice variation)                                 25261               2.89              0.00068
  Lgals3                              lectin, galactose binding, soluble 3                                                                    83781               2.31              0.00003
  Mmp2                                matrix metalloproteinase 2                                                                              17390               4.31              0.00000
  Plaur                               urokinase plasminogen activator receptor                                                                50692               2.93              0.00164
  Ptk2b                               protein tyrosine kinase 2 beta                                                                          50646               3.85              0.00000
  S100a4                              S100 calcium-binding protein A4                                                                         24615               3.61              0.00001
  Serpine1                            serine (or cysteine) proteinase inhibitor, clade E, member 1 (plasminogen activator inhibitor type 1)   24617               30.94             0.00003
  Stc1                                stanniocalcin 1                                                                                         81801               3.50              0.00306
  TEK                                 TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)                 7010                0.34              0.00012
  Tgfb2                               transforming growth factor, beta 2                                                                      81809               2.31              0.00458
  Tnfrsf12a                           tumor necrosis factor receptor superfamily, member 12a                                                  302965              2.91              0.00090

Genes also involved in adhesion\* and cell movement• of endothelial cells.

###### 

Genes involved in liver injury and abnormalities altered by comfrey-treatment

  **Gene symbol**                      **Gene description**                                                                                   **Locus link ID**   **Fold change**   ***P*-value**
  ------------------------------------ ------------------------------------------------------------------------------------------------------ ------------------- ----------------- ---------------
  *[Cell death of liver cells]{.ul}*                                                                                                                                                
  Bcl2                                 B-cell cLL/lymphoma 2                                                                                  24224               2.41              0.00500
  Bcl2l                                Bcl2-like                                                                                              12048               2.53              0.00000
  \*Ccr2                               chemokine receptor CCR2 gene                                                                           60463               2.47              0.00591
  Cdkn1a                               cyclin-dependent kinase inhibitor 1A (p21)                                                             114851              4.83              0.00014
  Cebpb                                CCAAT/enhancer binding protein (C/EBP), beta                                                           24253               0.46              0.00000
  Egf                                  epidermal growth factor                                                                                25313               0.36              0.00000
  Hmox1                                heme oxygenase 1                                                                                       24451               3.23              0.00064
  Ier3                                 immediate early response 3                                                                             294235              2.24              0.00002
  Itgav                                integrin alpha V                                                                                       16410               2.00              0.00113
  \*Krt2-8                             keratin complex 2, basic, gene 8                                                                       25626               2.82              0.00000
  Nos2                                 nitric oxide synthase 2, inducible                                                                     24599               3.38              0.00491
  \*, • Tgfb1                          transforming growth factor, beta 1                                                                     59086               2.11              0.00002
  Tnfrsf5                              tumor necrosis factor receptor superfamily, member 5                                                   21939               3.58              0.00009
  \*, • Tnfrsf6                        Tumor necrosis factor receptor superfamily, member 6                                                   246097              3.40              0.00007
  Tnfsf10                              tumor necrosis factor (ligand) superfamily, member 10                                                  246775              2.19              0.00366
  Ugcg                                 UDP-glucose ceramide glycosyltransferase                                                               83626               2.08              0.00000
  *[Growth of liver cells]{.ul}*                                                                                                                                                    
  Ccne1                                cyclin E1                                                                                              898                 7.93              0.00000
  Edn1                                 endothelin 1                                                                                           24323               4.87              0.00033
  \*, • Hgf                            hepatocyte growth factor                                                                               24446               3.18              0.00065
  Inhba                                inhibin beta-A (activin A)                                                                             29200               0.08              0.00000
  Tgfb1                                transforming growth factor, beta 1                                                                     59086               2.11              0.00002
  Timp1                                tissue inhibitor of metalloproteinase 1                                                                116510              4.25              0.00000
  *[Liver fibrosis]{.ul}*                                                                                                                                                           
  Adrb2                                adrenergic receptor, beta 2                                                                            24176               3.58              0.00000
  Agt                                  angiotensinogen                                                                                        24179               0.36              0.00000
  Agtr1a                               angiotensin II receptor, type 1 (AT1A)                                                                 24180               0.38              0.00000
  Atf3                                 activating transcription factor 3                                                                      25389               6.22              0.00010
  Cav                                  caveolin                                                                                               25404               3.15              0.00006
  Cxcl4                                chemokine (C-X-C motif) ligand 4                                                                       56744               3.12              0.00008
  Cxcl12                               chemokine (C-X-C motif) ligand 12                                                                      24772               0.19              0.00000
  F11                                  coagulation factor XI                                                                                  109821              0.43              0.00000
  Igf1                                 insulin-like growth factor 1                                                                           24482               0.48              0.00000
  Lif                                  leukemia inhibitory factor                                                                             60584               0.41              0.00215
  Serpine1                             serine (or cysteine) proteinase inhibitor, clade E member 1 (plasminogen activator inhibitor type 1)   24617               30.94             0.00003
  *[Liver morphology]{.ul}*                                                                                                                                                         
  Ccnd1                                cyclin D1                                                                                              58919               5.65              0.00002
  Ins1                                 insulin 1                                                                                              24505               0.22              0.00000
  Junb                                 Jun-B oncogene                                                                                         24517               3.77              0.00001
  *[Liver cancer development]{.ul}*                                                                                                                                                 
  Bcl2                                 B-cell cLL/lymphoma 2                                                                                  24224               2.41              0.00500
  Ccne1                                cyclin E1                                                                                              898                 7.93              0.00000
  Gadd45a                              growth arrest and DNA-damage-inducible 45 alpha                                                        25112               2.15              0.00326
  Gjb1                                 gap junction membrane channel protein beta 1                                                           29584               0.48              0.00003
  Hgf                                  hepatocyte growth factor                                                                               24446               3.18              0.00065
  Ndr1                                 N-myc downstream regulated 1 (Ndrg1)                                                                   10397               2.26              0.00020
  Timp1                                tissue inhibitor of metalloproteinase 1                                                                116510              4.25              0.00000
  Xpc                                  xeroderma pigmentosum, complementation group C                                                         7508                0.42              0.00001

\*Five genes also involved in liver fibrosis and • three genes also involved in liver morphology.
